Volume 10 Supplement 2
Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
© Ho and Kalicinsky; licensee BioMed Central Ltd. 2014
Published: 18 December 2014
The absolute risk of angiotensin-converting enzyme (ACE) inhibitor angioedema is 0.3% . The mechanism is felt to be accumulation of bradykinin. The current treatment is discontinuation of ACE-I inhibitor, and intubation if necessary. Icatibant is a bradykinin receptor antagonist, useful in treating hereditary angioedema . We present a patient from a Canadian center who had ACE-inhibitor induced angioedema requiring intubation who did not respond to epinephrine or C1 esterase inhibitor concentrate, then later responded favorably to Icatibant.
We present a case of a 76 year old male with hypertension, type II diabetes, no allergies, who was seen in the ER with acute new-onset tongue and facial swelling. He had a virus 2 weeks prior. His medications included quinapril, simvastatin, repaglinide, metformin, pioglitazone, and aspirin.
He had a swollen tongue, oral cavity, neck and was unable to swallow. There was no urticaria. He was given diphenhydramine 50mg IV, methylprednisolone 125mg IV, epinephrine 0.3mg IM, and ranitidine 50mg IV. Swelling progressed and he was intubated.
Over the next 24 hours, he received methylprednisolone 80mg every 8 hours, ranitidine 50mg every 8 hours, diphenhydramine 50mg every 6 hours, two doses of C1 esterase inhibitor concentrate, 1500 units IV followed by 1000 units. Quinipril was discontinued. Computed tomography of the neck showed no abscess.
Over the next 2 days there was minimal improvement. Therefore, on hospital day 3, he received 3 doses of Icatibant 30 mg over 24 hours. Improvement was noted, and by the next day, he was extubated. Following overnight monitoring, he was transferred to the medicine ward. There was no recurrence and he was discharged. C1 esterase inhibitor level and function was normal (drawn prior to infusion).
At his two month follow up he remained asymptomatic. ACE inhibitors and Angiotensin Receptor Blockers are avoided. He was diagnosed with myelodysplastic syndrome following work up for anemia noted on admission.
There have been published reports outside of Canada describing the use of Icatibant in ACE-inhibitor induced angioedema .
Icatibant is not indicated in Canada for ACE-inhibitor induced angioedema. However, it may need to be considered in severe cases.
Icatibant may be helpful in ACE-inhibitor induced angioedema when the patient has not responded to the discontinuation of the ACE inhibitor and alternative therapies.
Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
- Makani H, M F-P: Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. American Journal of Cardiology,. 2010, 110 (3): 383-91.View ArticleGoogle Scholar
- C P: AAAAI: Third Time a Charm for Novel HAE Drug. 2011, Retrieved July 13, 2014, from Med Page Today: http://www.medpagetoday.com/MeetingCoverage/AAAAI/25501Google Scholar
- Bas M, G J: Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series. Annual Emergency Medicine. 2010, 56 (3): 278-82. 10.1016/j.annemergmed.2010.03.032.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.